Gynecological Cancer Center of Excellence
Abstract
The Gynecological Cancer Center of Excellence focuses on characterizing the molecular alterations associated with benign and malignant gynecological disease and facilitates the development of novel early detection, prevention and novel biologic therapeutics for the management of gynecological disease. The GYN-COE leverages innovative research to enhance gynecologic cancer care from prevention to survivorship for service members, beneficiaries, and the civilian population. • To use extraordinary analytical capabilities in sample preparations combined with micro-scaled proteogenomic analysis for development of companion diagnostics, theragnostics, prognostics and prediction models for provision of precision medicine to gyn cancer patients as well as agnostically to all patients through pan cancer discovery • The throughput of our analytical facility will open up opportunities to expand our capabilities for proteogenomic tissue profiling of biopsy sized specimens to support ancillary studies of drug response and resistance in clinical trial patients aimed at repurposing of FDA-approved drugs for pan cancer treatment in partnership with public, private, and industry organizations. • Use of our technologies to support proteogenomic characterization of the world’s most rare and yet most clinically devastating diseases in partnership with the Joint Pathology Center. • Deployment of our analytical expertise to support research involving COVID related threats, combat related disorders, and behavioral health disorders, such as PTSD and others that are prevalent in retired veterans. • To expand our racial disparities research using the PAIRED consortium to support investigation of any cancer type or other disease for which there are worse outcomes in minority populations. • To provide undergraduate and graduate medical training in advanced pelvic surgery and complex gynecologic conditions within the context of a specialized fellowship in gynecologic oncology that produces physician scientists fluent in the latest advances of precision medicine for gynecologic cancer patients • Continue to serve as the comprehensive cancer center for gynecologic oncology clinical trial patients of the National Institutes of Health and veterans from regional VA facilities • The Clinical Proteomics Platform in the GYN-COE processed and analyzed 2224 unique cancer specimens in 2019 with a variance of less than 10%
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- e07bb9dfe5816570c92ec5b91e999f28